Xu Ting – Founder, Chairman & CEO, Alphamab Oncology, China

PharmaBoardroom caught up with Alphamab Oncology’s founder, chairman and CEO Dr Xu Ting again 16 months after our last interview to hear about their successful HKEX IPO in December 2019, his commercial expectations for their flagship PD-1/PD-L1 product, and the impact of COVID-19 on their operations.  
The core business – our research-driven, data-driven approach to innovation – has not changed [post-IPO]. We are committed to developing our portfolio and generating value for our stakeholders
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report